Previous 10 | Next 10 |
Aquestive Therapeutics, Inc. (AQST) Q3 2020 Results Earnings Conference Call November 05, 2020, 08:00 AM ET Company Participants Stephanie Carrington - IR, Westwicke Keith Kendall - President and Chief Executive Officer John Maxwell - SVP and Chief Financial Officer Dan Barber - SVP and Chief...
Image source: The Motley Fool. Aquestive Therapeutics, Inc. (NASDAQ: AQST) Q3 2020 Earnings Call Nov 05, 2020 , 8:00 a.m. ET Operator Continue reading For further details see: Aquestive Therapeutics, Inc. (AQST) Q3 2020 Earnings Call Tran...
Aquestive Therapeutics (AQST): Q3 GAAP EPS of -$0.49 misses by $0.04.Revenue of $8.3M (-33.1% Y/Y) misses by $0.42M.FY20 guidance: Total revenues of ~$42M-$46M vs consensus of $47.3M; Non-GAAP adjusted gross margins of ~70%-75%; Non-GAAP adjusted EBITDA loss of ~$38M-$42M; Cash burn of ~...
Sympazan® (clobazam) continues to meet key performance metrics and market penetration FDA Type A meeting for Libervant™ (diazepam) Buccal Film scheduled for November 12, 2020 Completed dosing in Phase 1 Pharmacokinetic (PK) trial for AQST-108 (epinephrine) Execut...
Beasley Broadcast Group (BBGI) +54% on Q3 results.Alaska Communications Systems Group (ALSK) +56% after announcing agreement to be acquired by Macquarie Capital and GCM Grosvenor for $3.0 per share.JAKKS Pacific (JAKK) +18% on Q3 results.trivago N.V. (TRVG) +15%....
Aquestive Therapeutics (AQST) +6.3% PM, entered a royalty monetization agreement with an affiliate of Marathon Asset Management, a leading global investment firm, leading to proceeds of up to $125M.As per agreement terms, Aquestive will receive $40M at closing and is eligible to receive ...
Receives $ 4 0 million of proceeds at closing , with potential $ 2 5 million of additional proceeds by mid-2022 Reduces outstanding debt to $5 1.5 million WARREN, N.J., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics...
WARREN, N.J., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that it will repo...
Recent disapproval from FDA regarding Libervant Buccal Film has seen investors react sourly over the last 2 weeks. Investors have punished the company, with the stock giving away ~-47% in returns over this period. Recent history shows the market can see the upside in Aquestive, an...
Blueprint gets European Union nod for Ayvakyt. Aquestive receives CRL for seizure clusters treatment Libervant. PMV Pharma makes impressive IPO debut, stock soars. For further details see: Blueprint European Approval, And Other News: The Good, Bad And Ugly Of Biopharma ...
News, Short Squeeze, Breakout and More Instantly...
Aquestive Therapeutics Inc. Company Name:
AQST Stock Symbol:
NASDAQ Market:
Aquestive Therapeutics Inc. Website:
Clearwater Paper Corporation (CLW) is expected to report for Q2 2024 Amgen Inc. (AMGN) is expected to report $4.93 for Q2 2024 Bain Capital Specialty Finance Inc. (BCSF) is expected to report $0.47 for Q2 2024 Axon Enterprise Inc. (AXON) is expected to report $0.55 for Q2 2024 Ame...
Meets primary study endpoints with pharmacokinetics (PK) comparable whether Anaphylm is administered by subjects or by healthcare providers (HCPs) Final supportive study, the Oral Allergy Syndrome (OAS) challenge study, currently enrolling Continues to anticipate requesting a pr...
WARREN, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technolog...